2024-02-12 22:59:06 ET
Summary
- Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share).
- Multiple FDA approvals, if forthcoming, in 2024 could prove to be material catalysts, perhaps highlighting that the company has operational assets beyond its cash.
- The market's current valuation of VNDA appears too pessimistic and a range of $5-10/share may be more reasonable, even assuming imperfect capital allocation.
- There could be further upside if drug approvals and operational performance go well in 2024.
- If things trend poorly, a valuation below $4/share is possible if operational performance is weak in 2024 and FDA approvals are not forthcoming.
Trading Below Cash
Vanda Pharmaceuticals (VNDA) should, in a sense, be a simple buy. It's trading below its December 2023 holdings of cash and marketable securities with two in-market products generating material revenue, another recently acquired, and the opportunity for three FDA approvals in 2024 in the best case....
Read the full article on Seeking Alpha
For further details see:
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash